Novocure Ltd (OQ:NVCR)

Business Focus: Medical Equipment

Sector:  Healthcare Industry:  Medical Equipment, Supplies & Distribution
 
See Regulatory Filings on SEC
Company Contact
Address: No. 4 The Forum, Grenville Street
SAINT HELIER JE2 4UF
Tel: N/A
Website: https://www.novocure.com
IR: See website
<
Key People
William F. Doyle
Executive Chairman of the Board
Asaf Danziger
President, Chief Executive Officer, Director
Ashley Cordova
Chief Financial Officer
Wilhelmus C. M. Groenhuysen
Chief Operating Officer
William Burke
Chief Human Resource Officer
Frank X. Leonard
Executive Vice President and President - Novocure Oncology
Barak Ben-Arye
General Counsel
Nicholas Leupin
Chief Medical Officer
Uri Weinberg
Chief Innovation Officer
Business Overview
NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
Financial Overview
For the fiscal year ended 31 December 2023, Novocure Ltd revenues decreased 5% to $509.3M. Net loss increased from $92.5M to $207M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Sales and marketing - Balancing value increase of 32% to $190.8M (expense), General and administrative - Balancing increase of 36% to $122.8M (expense), Research.
Employees: 1,453 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $1,058M as of Dec 31, 2023
Annual revenue (TTM): $509.34M as of Dec 31, 2023
EBITDA (TTM): -$221.89M as of Dec 31, 2023
Net annual income (TTM): -$207.04M as of Dec 31, 2023
Free cash flow (TTM): -$100.43M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 107,093,432 as of Feb 16, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.